Drugs / CD19/CD22 bispecific CAR-T cells
CD19/CD22 bispecific CAR-T cells
also known as
CAR2219
Cell therapy targets CD19, CD22 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07461831 | Feb 2022 → Apr 2026 overdue | large B-cell lymphoma | Beijing Tongren Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22 bispecific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07461831 ↗ |
| Known as | CAR2219 | “In this prospective study, the investigators aimed to evaluate the efficacy and safety of CD19/CD22 bispecific CAR-T cell (CAR2219) therapy in patients with R/R LBCL.” NCT07461831 ↗ |
| Action | Deplete | “enabling precise elimination of tumor cells.” NCT07461831 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor-T (CAR-T) cell therapy involves genetically engineering T cells to express chimeric antigen receptors (CARs)” NCT07461831 ↗ |
| Route | Other | “CD19/CD22-bispecific CAR-T cells were infused at the dosage of 2×10e6/kg” NCT07461831 ↗ |
| Target | CD19 | “targeting both CD19 and CD22” NCT07461831 ↗ |
| Target | CD22 | “targeting both CD19 and CD22” NCT07461831 ↗ |